Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | XBP1 | P17861 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13263726 | 0.88 | LIMK1 (0.30) | LIMK1 | |
| SCHEMBL27846918 | 0.79 | ALDH1A1 (0.36) | MAPK1KDM4EALDH1A1LIMK1 | |
| SCHEMBL1338574 | 0.79 | LIMK1 (0.40) | MAPK1KDM4EALDH1A1HTTLIMK1 | |
| SCHEMBL1338519 | 0.77 | CHUK (0.32) | MAPK1KDM4EALDH1A1LIMK1 | |
| SCHEMBL28793921 | 0.77 | MAPK1 (0.32) | MAPK1KDM4EALDH1A1LIMK1 | |
| SCHEMBL1338496 | 0.77 | MAPK1 (0.32) | MAPK1KDM4EALDH1A1LIMK1 | |
| SCHEMBL27687020 | 0.76 | ALDH1A1 (0.36) | MAPK1KDM4EALDH1A1LIMK1 | |
| SCHEMBL1338345 | 0.75 | MAPK1 (0.33) | MAPK1KDM4EALDH1A1 | |
| SCHEMBL1338515 | 0.74 | GABRP (0.37) | CACNA1HLIMK1 | |
| SCHEMBL1338636 | 0.71 | HTT (0.65) | KDM4EALDH1A1GLAHTTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102282144-A | Oxadiazole derivatives as sphingosine-1-phosphate 1 receptor agonists | — | 2011-12-14 | — | — | CN | disclosed |
| EP-2387571-A1 | OXADIAZOLE DERIVATIVES AS SLPL RECEPTOR AGONISTS | Almirall S.A. (ES) | 2011-11-23 | — | — | EP | disclosed |
| US-20110274657-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2011-11-10 | — | — | US | disclosed |
| US-20110274657-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2011-11-10 | — | — | US | disclosed |
| US-20110274657-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2011-11-10 | — | — | US | disclosed |
| US-8041930-B2 | Data processing apparatus and method for controlling thread access of register sets when selectively operating in secure and non-secure domains | ARM LIMITED (GB) | 2011-10-18 | — | — | US | disclosed |
| EP-2210890-A1 | Oxadiazole derivatives as S1P1 receptor agonists | Almirall, S.A. (ES) | 2010-07-28 | — | — | EP | disclosed |
| EP-2210890-A1 | Oxadiazole derivatives as S1P1 receptor agonists | Almirall, S.A. (ES) | 2010-07-28 | — | — | EP | disclosed |
| WO-2010081692-A1 | OXADIAZOLE DERIVATIVES AS SLPL RECEPTOR AGONISTS | ALMIRALL, S.A. (ES) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110274657-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS | S1PR1, S1PR3, S1PR2 | MAPK1 1697/4885CACNA1H 1141/4885KDM4E 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.